### Supplementary information to

# Mesenchymal Stem Cells Reversed Morphine Tolerance and Opioid-induced Hyperalgesia

Zhen Hua<sup>1,2</sup>\*, LiPing Liu<sup>1</sup>\*, Jun Shen<sup>1</sup>, Katherine Cheng<sup>1</sup>, Aijun Liu<sup>1</sup>, Jing Yang<sup>1</sup>, Lina Wang<sup>1</sup>, Tingyu Qu<sup>3</sup>, HongNa Yang<sup>3</sup>, Yan Li<sup>3</sup>, Haiyan Wu<sup>1</sup>, John Narouze<sup>1</sup>, Yan Yin<sup>1</sup>, Jianguo Cheng<sup>1</sup>

- Departments of Pain Management and Neurosciences,
   Lerner Research Institute and Anaesthesiology Institute, Cleveland Clinic,
   9500 Euclid Avenue, Cleveland, Ohio, USA 44195
- Department of Anesthesiology, Beijing Hospital, No.1 Dahua Road, Beijing, China 100730
- 3. Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA

#### **Correspondence:**

Jianguo Cheng, MD, PhD
Professor of Anesthesiology and Director of Pain Medicine Fellowship Program
Departments of Pain Management of Neurosciences, Cleveland Clinic
9500 Euclid Avenue/C25
Cleveland, Ohio, 44195
chengj@ccf.org


Running head: Stem cells reversed morphine tolerance and hyperalgesia

Introductory paragraph word count: 195; Text word count: 1499; Figures: 4;

Supplementary Figures: 3; Table: 0; References: 34

<sup>\*</sup> Drs. Hua and Liu equally contribute to this work.


#### **Supplement Figure 1**



**Supplement Figure 1**. **Induction of opioid tolerance (OT) and opioid-induced hyperalgesia (OIH). (a)** Acute tolerance. Agonist dose-response curves were constructed with increasing doses of morphine (MS) (0–18 mg/kg) in rats that had received 3 days of daily injections of normal saline (NS) or MS (7.5mg/kg). The Plantar test was used to construct the dose-response curves 30 min after third day of daily NS or MS injection. (MS: n=5 and NS: n=3, thermal


response cutoff time: 25s; #P<0.01; \*P<0.05 between groups). (b) Chronic tolerance assessed by mechanical stimulation. Rats were treated with MS daily for 3-4 weeks. Paw withdrawal thresholds to mechanical stimulation by von Frey filaments were tested before and 50 min after MS injection. The difference between the two measurements indicates responsiveness to MS. A large difference indicates low or no tolerance while a small difference indicates high tolerance (n=8, \*P<0.05 compared the mean value recorded in Day 1 of MS injection). (c) Chronic tolerance assessed by tail flick test. Maximum possible effect (MPE) of MS was used to indicate tolerance. The lower the MPE (%) the higher the tolerance (n=12, \*P < 0.05 compared the mean value recorded in Day 1 of MS injection). (d) Chronic OIH. PWTs were assessed by von Frey filament before daily MS injections. The progressive declining of PWTs indicates hyperalgesia in response to daily morphine injections (n=6, #P<0.01; \*P<0.05 compare to the NS control group). (e, f) In normal rats, PWTs did not change in response to intrathecal (e) or intravenous (f) injection of PBS or MSCs (0.5x 10<sup>6</sup>) (n=6-8). Data: mean± s.e. IT, intrathecal; IV, intravenous; MPE, maximal possible effect; MS, morphine sulfate; NS, normal saline; PWT, paw withdrawal threshold.

## **Supplement Figure 2**



Supplement Figure 2. MSC-TP reversed OT induced by daily morphine injections in rats. Decreasing PWT difference between the measurements made before and 30 min after MS injection indicates OT. \* P<0.05 compared with same day PBS; # P<0.05 compared with PBS Day 1; + P<0.05 compared with MSC Day 1. n=12 in each group. Please note the sham control group (injection with saline) was not included for clarity. The effect of morphine injection is reflected by increased PWTs (larger Y axis scale).

#### **Supplement Figure 3**



Group	ALT(U/L)	Cholesterol (mg/dL)	Glucose(mg/dL)	BUN(mg/dL)	Creatinine(mg/dL)
NS	63.7±3	92.7±3	155.0±9	18.0±1.1	0.2±0
MS	70.3±3	91.3±7	151.7±10	18.6±2.2	0.2±0
IT MSC	60.0±9	86.3±3	143.3±10	18.4±2.5	0.3±0.1
IV MSC	75.8±6	96.3±5	152.8±21	18.6±2.8	0.2±0.2

Supplement Figure 3. Long term safety of MSC transplantation (MSC-TP). (a) Body weight gain was not affected by MSC-TP. Daily MS injections slightly but significantly reduced body weight gain compared to the NS control group (P<0.05 in many time-points between Days 24 and 68). However, there were no significant differences between the MS group and the MS+MSC group (P>0.05). NS group n=6, MS group n=11, MS+MSC group n=12. Data mean± s.e. (b) Normal liver and kidney functions after long-term MSC-TP. Blood plasma was collected from rats at the end of the experiments (55 days after MSC-TP). Biochemical tests for liver function (ALT, cholesterol and glucose) and kidney function (BUN, creatinine) were performed. Data: mean± s.e. P>0.05. n=6 each group. MS, morphine sulfate; MSC, mesenchymal stem cell; NS: normal saline.